相关实验视频
Updated: Jan 13, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
901
与肥胖相关的HFpEF药物疗法的进展:全面审查
Ying Wu1,2, Meiyan Song1,2, Xiaomin Chen1,2
1Department of Cardiology, Affiliated Hospital of Putian University, Putian, China.
Current heart failure reports
|October 29, 2025
概括
新的基于英克雷丁的疗法显著改善了心力衰竭的症状,并减少了肥胖患者的体重. 需要进一步的研究来确认与肥胖相关的HFpEF的长期益处和最佳组合策略.
科学领域:
- 心脏病学 心脏病学
- 代谢疾病 代谢疾病
- 药理学 药理学 是一个学科.
背景情况:
- 全球肥胖流行病正在增加心力衰竭率,其中保留喷射分数 (HFpEF).
- 与肥胖相关的HFpEF与非肥胖的HFpEF相比呈现出更大的症状,炎症和降低的生活质量.
- 生活方式的改变至关重要,但通常具有有限的坚持;减肥手术提供了显著的体重减轻,但缺乏HFpEF特定的结果数据.
研究的目的:
- 审查与肥胖相关的心力衰竭与保存的喷射分数 (HFpEF) 治疗的最新进展.
- 评估新型治疗剂在肥胖人群中管理HFpEF的疗效和潜力.
- 确定最佳的基于证据的策略来管理与肥胖相关的HFpEF.
主要方法:
- 审查最近的里程碑式临床试验,包括STEP-HFpEF,STEP-HFpEF DM和SUMMIT.
- 对HFpEF患者的基于胰岛素的疗法 (GLP-1RAs,双GIP/GLP-1RAs),SGLT2抑制剂和MRAs的数据分析.
- 评估其他药物如RNAI和HU6的证据,并考虑组合疗法.
主要成果:
- 基于因克雷丁的疗法 (GLP-1RAs和双GIP/GLP-1RAs) 显著改善HFpEF症状,减少心力衰竭恶化,并促进肥胖患者的体重减轻,无论糖尿病状况如何.
- -葡萄糖携带转运体-2 抑制剂和非类固醇矿物质皮质体受体对抗剂显示出预后益处,在较高的BMI亚组中可能更大.
- 基于英克雷丁的治疗方法的长期心血管死亡益处和安全概况需要进一步调查. 在这种情况下,RNAI和HU6缺乏足够的随机试验数据用于常规使用.
结论:
- 基于因克雷丁的疗法在管理与肥胖相关的HFpEF方面取得了重大进展,可缓解症状并减轻体重.
- 基于英克雷丁的疗法,SGLT2抑制剂和非类固醇MRA的组合可能是目前最佳的基于证据的策略.
- 未来的研究应该集中在标准化肥胖的定义,确定最佳的减肥目标,探索组合疗法,并评估长期结果.
相关概念视频
01:30Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
01:22Heart Failure VI: Adjunct Therapies
246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
235
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
235
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
01:26Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915